GlassScriptPhysician profile
Horidel Febo
NPI 1265540678
$6,723.77
in general payments reported to CMS, 2019-2025
12 companies · $573 in 2025
The $573 reported for 2025 was more than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $4,160 · 2020: $41.73 · 2021: $782 · 2022: $501 · 2023: $113 · 2024: $555 · 2025: $573.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,240.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,239.80 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $3,199.99 | 2019 | |
| Novo Nordisk INC | $996.45 | 2019-2025 | Ozempic, Rybelsus |
| Astrazeneca Pharmaceuticals LP | $718.68 | 2019-2025 | Farxiga |
| Lilly USA, LLC | $356.13 | 2024-2025 | Zepbound, Mounjaro |
| Amgen INC. | $355.68 | 2021-2025 | Repatha |
| Sanofi-Aventis U.S. LLC | $336.96 | 2019-2024 | |
| Janssen Pharmaceuticals, INC | $243.14 | 2019 | |
| Genentech USA, INC. | $125.00 | 2019 | |
| Corcept Therapeutics | $124.92 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $124.50 | 2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $112.50 | 2023 | Jardiance |
| Medtronic, INC. | $29.82 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Horidel Febo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.